Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The depolarising neuromuscular blocking agent suxamethonium chloride, frequently used during endotracheal intubation, is contraindicated in patients with chronic denervation in whom it can cause a life-threatening hyperkalaemic reaction, thought to be mediated through upregulation of nicotinic alpha7 acetylcholine receptors. An underlying neuromuscular disorder should be considered in all patients with acute respiratory insufficiency, and an alternative neuromuscular blocking drug must be used if there is any possibility of widespread denervation.

More information Original publication

DOI

10.7861/clinmedicine.11-3-292

Type

Journal article

Publication Date

2011-06-01T00:00:00+00:00

Volume

11

Pages

292 - 293

Total pages

1

Keywords

Amyotrophic Lateral Sclerosis, Fasciculation, Fatal Outcome, Female, Humans, Hyperkalemia, Intubation, Intratracheal, Middle Aged, Neuromuscular Depolarizing Agents, Succinylcholine, Tachycardia